ProCE Banner Activity

NRG1: An Emerging Tumor-Agnostic Target

Slideset Download
Review this slideset on applying emerging research to biomarker testing and treatment strategies for patients with NRG1 fusion–driven cancers by Stephen V. Liu, MD, and Ryma Benayed, PhD.

Released: February 02, 2022

Expiration: February 01, 2023

Share

Faculty

Ryma Benayed

Ryma Benayed, PhD

Associate Attending
Department of Pathology
Director, Clinical NGS Laboratory
Molecular Dx Service
Memorial Sloan Kettering Cancer Center
New York, New York

Stephen Liu

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Elevation Oncology

Partners

American Society for Clinical Pathology

ProCE Banner

Faculty Disclosure

Primary Author

Ryma Benayed, PhD

Associate Attending
Department of Pathology
Director, Clinical NGS Laboratory
Molecular Dx Service
Memorial Sloan Kettering Cancer Center
New York, New York

Ryma Benayed, PhD, has disclosed that she has received consulting fees from Hitachi, Loxo Oncology, and Roche Dx and fees for non-CME/CE services from Illumina.

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Stephen V. Liu, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, BeiGene, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead Sciences, Guardant Health, Janssen, Jazz, Lilly, Merck/MSD, Novartis, Regeneron, Takeda, and Turning Point Therapeutics and funds for research support (paid to his institution) from Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Lilly, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, and Turning Point Therapeutics.